Abstracts tagged "Renal"

Abstract Number: 1285 • ACR Convergence 2021
Major Determinants of Prolonged Remission in Systemic Lupus Erythematosus: Retrospective Study over a 41-Year Period
Goncalo Durao-Carvalho¹, Raquel Fernandez², Bethan Goulden³, Filipa Farinha⁴ and David Isenberg⁵, ¹Servico de Medicina Interna, Centro Hospitalar do Oeste – Unidade de Caldas da Rainha, Caldas da Rainha, Portugal, Caldas da Rainha, Portugal, ²Servicio de Medicina Interna, Hospital Universitario de Ourense, Ourense, Spain, ³Department of Rheumatology, University College London Hospitals, London, United Kingdom, ⁴Department of Rheumatology, University College London Hospitals and Centre for Rheumatology, University College London, London, United Kingdom, ⁵Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Disease activity is a major determinant of mortality whereas prolonged remission contributes to improving health outcomes in SLE patients (pts). Remission is thus a…
Abstract Number: 1289 • ACR Convergence 2021
Patients Enrolled in the Accelerating Medicines Partnership (AMP) RA/SLE Network with Isolated Renal Disease Report Minimal Quality of Life Impairment on PROMIS-29 Compared to Patients with Extrarenal Symptoms
Philip Carlucci¹, Jessica Li², Heather Gold³, Kristina Deonaraine¹, Andrea Fava², Jill Buyon⁴, Judith James⁵, Chaim Putterman⁶, Deepak Rao⁷, Betty Diamond⁸, Derek Fine², Jose Monroy-Trujillo², Kristin Haag⁹, Accelerating Medicines Partership (AMP) RA/SLE Network¹⁰, H. Michael Belmont⁴, Sean Connery¹¹, Fernanda Payan-Schober¹², Richard Furie¹³, Celine Berthier¹⁴, Maria Dall'Era¹⁵, Kerry Cho¹⁶, Diane Kamen¹⁷, Kenneth Kalunian¹⁸, The Accelerating Medicines Parternship In SLE Network¹⁹, Peter Izmirly¹ and Michelle Petri²⁰, ¹New York University School of Medicine, New York, NY, ²Johns Hopkins University, Baltimore, MD, ³NYU Grossman School of Medicine, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Albert Einstein College of Medicine, Bronx, NY, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Northwell Health, Manhasset, NY, ⁹Johns Hopkins School of Medicine, Baltimore, MD, ¹⁰Brigham and Women's Hospital, Everett, MA, ¹¹Texas Tech University Health Sciences Center, Texas, TX, ¹²Texas Tech University Health Sciences Center, El Paso, TX, ¹³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ¹⁴University of Michigan, Ann Arbor, MI, ¹⁵University of California San Francisco, Corte Madera, CA, ¹⁶University of California San Francisco, San Francisco, CA, ¹⁷Medical University of South Carolina, Charleston, SC, ¹⁸UC San Diego, La Jolla, CA, ¹⁹Multiple Institutions, Multiple Cities, ²⁰Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Lupus nephritis can occur as an isolated component of disease activity or be accompanied by diverse extrarenal symptoms that can adversely affect a patient’s…
Abstract Number: 1482 • ACR Convergence 2021
LN Urinary Proteomics Reveals Common Biological Pathways Identified by Distinct Disease Measures
Paul Newcombe¹, Madhu Ramaswamy², Dominic Sinibaldi², Catharina Lindholm³, Frederick Jones¹, Ahmad Akhgar², Philip Brohawn², Raj Tummala² and Wendy White², ¹BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ²BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ³BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Background/Purpose: LN is a severe consequence of SLE and there is a huge unmet need for discovery of urine protein biomarkers that provide non-invasive surrogates…
Abstract Number: 1568 • ACR Convergence 2021
AR882, a Potent and Selective Uricosuric Agent, Showed Effectiveness in Patients with Various Degrees of Renal Impairment
zancong shen¹, Elizabeth Polvent², vijay hingorani³, Rongzi Yan⁴, Shunqi Yan⁵ and Litain Yeh⁶, ¹Arthrosi Therapeutics, Inc., San Diego, CA, ²Arthrosi Therapeutics, Inc., Roseville, CA, ³Vanguard Healthsciences, Inc., San Diego, CA, ⁴Arthrosi Therapeutics, Inc, Irvine, CA, ⁵Arthrosi Therapeutics, Inc., Laguna Hills, CA, ⁶Arthrosi Therapeutics, Inc., Irvine, CA
Background/Purpose: AR882 is a novel, potent and selective uric acid transporter 1 (URAT1) inhibitor in Phase 2 development for the treatment of hyperuricemia and gout.…
Abstract Number: 1757 • ACR Convergence 2021
Clinical Use of Belimumab for Systemic Lupus Erythematosus in the Setting of Advanced Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: A Case Series
Matthew Snyder¹, Angel Chen¹, Sonali Narain² and Galina Marder², ¹Donald and Barbara Zucker School of Medicine at Hofstra/Northwell at Lenox Hill Hospital Program, New York, NY, ²Northwell Health, Great Neck, NY
Background/Purpose: Belimumab is FDA approved for treatment of SLE and Lupus Nephritis. Patients with an eGFR < 30 ml/min/1.73m2 were excluded from clinical trials, thus…
Abstract Number: 1937 • ACR Convergence 2021
IL-16 Is Linked to Lupus Nephritis Activity
Andrea Fava¹, Deepak Rao², Chandra Mohan³, Ting Zhang³, Avi Rosenberg¹, Paride Fenaroli⁴, H. Michael Belmont⁵, Peter Izmirly⁶, Robert Clancy⁷, Jose Monroy-Trujillo¹, Derek Fine¹, Arnon Arazi⁸, Celine Berthier⁹, Anne Davidson¹⁰, Judith James¹¹, Betty Diamond¹², Nir Hacohen¹³, David Wofsy¹⁴, Soumya Raychaudhuri², Accelerating Medicines Partership (AMP) RA/SLE Network¹⁵, Jill Buyon⁵, Michelle Petri¹⁶ and The Accelerating Medicines Partnership in RA/SLE¹⁷, ¹Johns Hopkins University, Baltimore, MD, ²Brigham and Women's Hospital, Boston, MA, ³University of Houston, Houston, TX, ⁴Universita` degli Studi di Parma, Parma, Italy, ⁵NYU School of Medicine, New York, NY, ⁶New York University School of Medicine, New York, NY, ⁷NYU Grossman School of Medicine, New York, NY, ⁸Feinstein Institutes for Medical Research, Melrose, MA, ⁹University of Michigan, Ann Arbor, MI, ¹⁰Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Northwell Health, Manhasset, NY, ¹³Broad Institute, Cambridge, MA, ¹⁴University of California San Francisco, San Francisco, CA, ¹⁵Brigham and Women's Hospital, Everett, MA, ¹⁶Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁷Multiple Institutions, Multiple
Background/Purpose: There is a pressing need to identify novel therapeutic targets in lupus nephritis. Multiomic approaches hold great potential for discovery. We integrated urine proteomics…
Abstract Number: 0327 • ACR Convergence 2021
Lipoprotein(a) in Systemic Lupus Erythematosus Is Associated with History of Proteinuria and Renal Insufficiency
Caoilfhionn Connolly¹, Jessica Li², Daniel Goldman³, Andrea Fava², Laurence Magder⁴ and Michelle Petri³, ¹Johns Hopkins, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: Lipoprotein(a) [Lp(a)] is a well-recognized, independent risk factor for atherosclerotic cardiovascular disease. Cardiovascular disease is one of the leading causes of death in patients…
Abstract Number: 0419 • ACR Convergence 2021
Post-induction ANCA Titer Does Not Predict Mortality or Renal Outcomes: A Target Trial Emulation Study
Gregory McDermott¹, Xiaoqing Fu², Claire Cook³, John Stone⁴, Yuqing Zhang⁵ and Zachary Wallace⁶, ¹Brigham and Women's Hospital, Brookline, MA, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Boston, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Harvard Medical School, Boston, MA, ⁶Massachusetts General Hospital, Newton, MA
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is associated with increased risk of end-stage renal disease (ESRD) and death. In most cases, circulating ANCA targeting…
Abstract Number: 0423 • ACR Convergence 2021
Urine and Plasma Complement Ba Levels During Flares of Nephritis in Patients with ANCA-Associated Vasculitis
Salem Almaani¹, Huijuan Song², Meshora Sthanithra², Christopher Toy², Anna Levesque², Lynn Fussner³, Alexa Meara³, Haikady Nagaraja², David Cuthbertson⁴, Nader Khalidi⁵, CURRY LEE MD KOENING⁶, Carol Langford⁷, Carol McAlear⁸, Larry Moreland⁹, Christian Pagnoux¹⁰, Philip Seo¹¹, Antoine Sreih¹², Kenneth Warrington¹³, Paul Monach¹⁴, Peter Merkel⁸, Brad Rovin³ and Dan Birmingham², ¹Ohio State University Medical Center, Columbus, OH, ²Ohio State university, Columbus, OH, ³Ohio State University Wexner Medical Center, Columbus, OH, ⁴University of South Florida, Tampa, FL, ⁵McMaster University, Hamilton, ON, Canada, ⁶LIMITED TO OFFICIAL UNIVERSITY DUTIES ONLY, Salt Lake City, UT, ⁷Cleveland Clinic, Moreland Hills, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹University of Colorado, Denver, CO, ¹⁰Mount Sinai Hospital, Toronto, ON, Canada, ¹¹Johns Hopkins University, Baltimore, MD, ¹²Univeristy of Pennsylvania, Philadelphia, PA, ¹³Mayo Clinic, Rochester, Minnesota, ¹⁴Brigham and Women's Hospital, Boston, MA
Background/Purpose: The alternative complement pathway has been implicated in the pathogenesis of ANCA-associated vasculitis (AAV), however it is not clear whether activation of complement occurs…
Abstract Number: 0665 • ACR Convergence 2021
Pegloticase Treatment for Uncontrolled Gout in Kidney Transplanted Patients: Results of an On-going Multicenter, Open-Label, Efficacy and Safety Study
Abdul Abdellatif¹, Lin Zhao², Paul M. Peloso³, Katya Cherny², Brad Marder², John D. Scandling⁴ and Kenneth Saag⁵, ¹Kidney Hypertension Transplant Clinic Clear Lake Specialties, Webster, TX, ²Horizon Therapeutics plc, Deerfield, IL, ³Horizon Therapeutics plc, Gurnee, IL, ⁴Stanford Medicine, Department of Nephrology, Stanford, CA, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Gout in kidney transplant (KT) recipients can be severe and particularly challenging to manage. Pegloticase (pegylated recombinant uricase) rapidly metabolizes urate and is a…
Abstract Number: 0875 • ACR Convergence 2021
Renal Function, Adherence and Low Hydroxychloroquine Dosing Predict HCQ Blood Levels and Lupus Disease Activity
Shivani Garg¹, Karen Hansen², Betty Chewning¹ and Christie Bartels², ¹UW Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Despite weight-based dosing, hydroxychloroquine (HCQ) efficacy varies between individuals. Our meta-analysis based on several studies found that low HCQ levels increased risk of lupus…
Abstract Number: 1387 • ACR Convergence 2020
Should Systemic Sclerosis Patients with Low Bicarbonate Have Replacement to Prevent Renal Dysfunction?
Megan Meier¹, Jacob Stever², Josephine Wright¹, Tracy Frech³, Greg Stoddard¹ and Benjamin Tingey¹, ¹University of Utah, Salt Lake City, ²University of Utah, SANDY, ³University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT
Background/Purpose: Scleroderma renal crisis (SRC) is a well-characterized condition in patients with systemic sclerosis, but systemic sclerosis patients frequently develop chronic kidney disease (CKD) without…
Abstract Number: 1425 • ACR Convergence 2020
Reduced Risk of Cardiovascular Diseases Events with Renal Transplantation in Granulomatosis with Polyangiitis in the United States: Data from the US Renal Data System
Zachary Wallace¹, April Jorge², Xiaoqing Fu³, Yuqing Zhang⁴ and Hyon Choi⁵, ¹Massachusetts General Hospital, Newton, MA, ²Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital, Boston, ⁴Massachusetts General Hospital, Quincy, MA, ⁵Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA
Background/Purpose: Granulomatosis with polyangiitis (GPA) is a common cause of glomerulonephritis and leads to end-stage renal disease (ESRD) in approximately 25% of patients. Both GPA…
Abstract Number: 1512 • ACR Convergence 2020
Trajectory Analysis of Repeat Renal Biopsies Identified Previous Endocapillary Proliferation as Predictor of Damage and End Stage Renal Disease in Pure Membranous Lupus Nephritis
Andrea Fava¹, Avi Rosenberg², Serena Bagnasco², Paride Fenaroli², Jessica Li¹, Jose Monroy-Trujillo², Derek Fine² and Michelle Petri³, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University, Baltimore, ³Johns Hopkins University School of Medicine, Baltimore
Background/Purpose: . Pure membranous (class V) lupus nephritis is considered a less aggressive phenotype, but renal fibrosis and chronic kidney disease may develop. Whether this…
Abstract Number: 1514 • ACR Convergence 2020
The Impact of Renal Transplantation on Cardiovascular Events Among Patients with End-State Kidney Disease Due to Lupus Nephritis: A Nationwide Cohort Study
April Jorge¹, Xiaoqing Fu², Yuqing Zhang³, Hyon Choi⁴ and Zachary Wallace⁵, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Harvard Medical School, Boston, ⁴Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA, ⁵Harvard Medical School, Boston
Background/Purpose:A major complication of systemic lupus erythematosus (SLE) is the progression of lupus nephritis (LN) to end-stage kidney disease (ESKD). Both SLE and ESKD are…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.